Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Medtronic
Baxter
McKinsey
Johnson and Johnson

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR FLUOCINOLONE ACETONIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Fluocinolone Acetonide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00008515 ↗ Fluocinolone Implant to Treat Macular Degeneration Completed National Eye Institute (NEI) Phase 1 2001-01-01 This study will test the safety and effectiveness of a fluocinolone implant to treat age-related macular degeneration. This eye disease can severely impair central vision, affecting a person's ability to read, drive, and carry out daily activities. It is the leading cause of vision loss in people over age 60. The fluocinolone implant is a tiny plastic rod with a pellet of the steroid fluocinolone on the end. The pellet slowly dissolves and releases the medication into the fluid in the eye. Vision loss in macular degeneration is caused by the formation of new blood vessels in the choroid-a thin, pigmented vascular layer of the eye behind the retina. These abnormal vessels leak blood under the macula, the part of the retina that determines central vision. Tissue studies show evidence of inflammation in the retinas of patients. This study will test whether the slow release of the steroid fluocinolone directly into the affected part of the eye can prevent or slow further vision loss. Preliminary animal and human studies with fluocinolone implants have shown some benefit in reducing blood vessel growth and improving or stabilizing vision. Patients 50 years of age and older with age-related macular degeneration may be eligible for this study. Study patients will be randomly assigned to one of two treatment groups. One will receive a 0.5-mg dose implant; the other will receive a 2-mg dose implant. Theoretically, the implants can release the medicine for 2 to 3 years. Participants will have a medical history, physical examination and complete eye examination. The latter will include a vision test, eye pressure measurement, examination of the pupils, lens, retina, and eye movements. Photographs of the eye will be taken with a special camera. Patients will also undergo fluorescein angiography, a test that takes pictures of the retina using a yellow dye called sodium fluorescein. The dye is injected into the blood stream through a vein. After it reaches the blood vessels of the eye, photographs are taken of the retina. When the above tests are completed, patients will be scheduled for surgery to place the implant. The procedure will be done under either local or general anesthesia. Follow-up visits will be scheduled 1, 2, 4, and 6 weeks after surgery, then at 3 and 6 months after surgery, and then every 6 months until the implant is depleted of medicine or is removed. Several of the exams described above will be repeated during the follow-up period to evaluate the treatment and side effects, if any.
NCT00132691 ↗ Multicenter Uveitis Steroid Treatment (MUST) Trial Completed National Eye Institute (NEI) Phase 4 2005-09-01 The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
NCT00132691 ↗ Multicenter Uveitis Steroid Treatment (MUST) Trial Completed JHSPH Center for Clinical Trials Phase 4 2005-09-01 The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fluocinolone Acetonide

Condition Name

Condition Name for Fluocinolone Acetonide
Intervention Trials
Diabetic Macular Edema 9
Uveitis 4
Uveitis, Posterior 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fluocinolone Acetonide
Intervention Trials
Uveitis 12
Macular Edema 11
Edema 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluocinolone Acetonide

Trials by Country

Trials by Country for Fluocinolone Acetonide
Location Trials
United States 87
India 16
United Kingdom 5
Australia 3
China 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fluocinolone Acetonide
Location Trials
Maryland 8
North Carolina 6
Massachusetts 5
Georgia 5
California 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluocinolone Acetonide

Clinical Trial Phase

Clinical Trial Phase for Fluocinolone Acetonide
Clinical Trial Phase Trials
Phase 4 11
Phase 3 9
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fluocinolone Acetonide
Clinical Trial Phase Trials
Completed 20
Terminated 4
Not yet recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluocinolone Acetonide

Sponsor Name

Sponsor Name for Fluocinolone Acetonide
Sponsor Trials
Alimera Sciences 7
Bausch & Lomb Incorporated 6
EyePoint Pharmaceuticals, Inc. 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fluocinolone Acetonide
Sponsor Trials
Industry 27
Other 14
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
McKinsey
Dow
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.